CStone gains China rights to Blueprint programs

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million.

CStone gained exclusive rights to develop and commercialize avapritinib, BLU-667 and BLU-554 in mainland China, including Hong Kong and Macau, and Taiwan for use as monotherapies or in combination therapies. Blueprint will receive $40 million in cash up front and is eligible for $118.5 million in development and regulatory milestones and $227.5 million in sales-based milestones. Blueprint is also eligible to receive tiered royalties ranging from the mid-teens to low twenties...